Authorized purpose: cvi42 Coronary Plaque supports qualified professionals with viewing, post-processing, and qualitative and quantitative evaluation of adult cardiac CT DICOM images to assess the presence and extent of coronary plaques and stenoses in CCTA for CAD or suspected CAD.
Clinical role
Post-processing and semi-automated plaque and stenosis assessment to provide qualitative and quantitative information for physician review.
Images and patients
CT/CTA · Heart/Cardiovascular
Key limitation
Keep in mind: The software is an adjunct to comprehensive physician interpretation, is limited to cardiac CT from a CT scanner, and its semi-automated algorithms are intended for adults. The public K251027 packet does not establish clinical outcomes or product-wide diagnostic accuracy beyond the reported regulatory endpoints.
Clinical detailsPurpose, workflow fit, evidence, and safety record
Workflow navigation pilot
Workflow role has not yet been reviewed for this navigation pilot.
A tag identifies a documented role; it does not establish compatibility or local acceptance. Methods and sources
What does this software do?Authorized purpose: cvi42 Coronary Plaque supports qualified professionals with viewing, post-processing, and qualitative and quantitative evaluation of adult cardiac CT DICOM images to assess the presence and extent of coronary plaques and stenoses in CCTA for CAD or suspected CAD.
Which images or clinical context are in scope?Modality: CT/CTA Anatomy or clinical context: Heart/Cardiovascular Input: Adult cardiac CT images acquired from a CT scanner in DICOM format for CCTA evaluation of CAD or suspected CAD.
Who uses it?Intended users: Qualified medical professionals experienced in examining cardiovascular CT images as part of comprehensive diagnostic decision-making.
What does the software produce?Output: Calcified, non-calcified, low-attenuation, and total plaque volumes and burdens; remodeling index; diameter- and area-based stenosis; lesion length; on-screen results and a Coronaries Plaque Module report.
What is its most important limitation?Key limitation: The software is an adjunct to comprehensive physician interpretation, is limited to cardiac CT from a CT scanner, and its semi-automated algorithms are intended for adults. The public K251027 packet does not establish clinical outcomes or product-wide diagnostic accuracy beyond the reported regulatory endpoints.
Clinical takeaway. Clinical role: cvi42 Coronary Plaque supports qualified professionals with viewing, post-processing, and qualitative and quantitative evaluation of adult cardiac CT DICOM images to assess the presence and extent of coronary plaques and stenoses in CCTA for CAD or suspected CAD.
Evidence takeaway. Evidence from the reviewed source record: K251027 FDA evidence is a regulatory ML segmentation and plaque-volume validation package; no independent publication or trial was promoted in this review.
Evidence context
Evidence context not reviewed for this FDA record.
Public-label constraints
Label constraints have not been reviewed for this exact FDA record. Unknown is not all ages or evidence of unsuitability.
Public-label constraints, not patient-level eligibility or a medical recommendation. Training and evaluation populations are separate. Read the original labeling and confirm the exact release and protocol.
Purpose
cvi42 Coronary Plaque supports qualified professionals with viewing, post-processing, and qualitative and quantitative evaluation of adult cardiac CT DICOM images to assess the presence and extent of coronary plaques and stenoses in CCTA for CAD or suspected CAD.
Calcified, non-calcified, low-attenuation, and total plaque volumes and burdens; remodeling index; diameter- and area-based stenosis; lesion length; on-screen results and a Coronaries Plaque Module report.
The software is an adjunct to comprehensive physician interpretation, is limited to cardiac CT from a CT scanner, and its semi-automated algorithms are intended for adults. The public K251027 packet does not establish clinical outcomes or product-wide diagnostic accuracy beyond the reported regulatory endpoints.
K251027 FDA evidence is a regulatory ML segmentation and plaque-volume validation package; no independent publication or trial was promoted in this review.
Metrics are shown only when they are tied to a source, endpoint, population, and tested product version. Candidate literature without exact product and version linkage is not shown as product evidence.
Evidence summary
K251027 FDA evidence is a regulatory ML segmentation and plaque-volume validation package; no independent publication or trial was promoted in this review.
K251027 machine-learning validation of the Coronary Plaque Module
DesignRetrospective regulatory validation against reference standards established by three expert annotators; development and validation images were separated.
PopulationAdult cardiac CT/CCTA images from multiple U.S. sources and major CT vendors
Scopeexact submission
Tested versioncvi42 Coronary Plaque Software Application configuration described in K251027
IndependenceSponsor or vendor study
K251027
Manufacturer-submitted FDA evidence; it is not an independent clinical-outcome study.
Recall and adverse-event records are shown only after product matching. Adverse-event reports do not establish incidence or causality.
Postmarket safety review
The wave22 exact-submission recall query returned no native recall record for K251027. This does not establish absence of family, later-version, or adverse-event information.
CMS LCD L39913 v7 and Article A59813 v6 provide conditional service-level policy context for AI-QCT/AI-CPA after completed and interpreted CCTA in WPS Medicare J5/J8 for selected symptomatic chest-pain patients; exact product/version eligibility and individual claim eligibility are not established.
Product family
Checked 2026-09-07
Service-level policy context; exact product/version and individual claim eligibility are not established. This is not a product code assignment, universal Medicare coverage determination, fee, or price.
Medicare / WPS · United States - WPS J5/J8 jurisdictions · Effective 2026-01-01
CMS policy context applies to an eligible CCTA plaque-analysis service in a limited WPS policy scope; it does not assign coverage to K251027 or establish individual claim eligibility.
IT implementationDeployment, interfaces, data handling, and support
System and version relationships
Match the AI release, system build, configuration and region. Source documentation does not establish acceptance of an installed system.
No specific system/version pairing has completed review for this FDA record. A broad DICOM or product-family statement does not establish a named viewer build's support.
Public source context, not tested interoperability. Each hop needs its own release/configuration evidence. Missing or unavailable routes are not documented incompatibility. All local tests are planned, not passed; no installed-system acceptance is recorded.
Acquisition/source → routing → AI processing → returned objects → viewer/worklist/report → support owner
No specific route context has been source-reviewed for this record. Obtain both endpoint builds and documents; this is not a finding of incompatibility.
Acquisition/source
Source context, not route validation: Adult cardiac CT images acquired from a CT scanner in DICOM format for CCTA evaluation of CAD or suspected CAD.
Scope: Exact FDA submission.
Confirm scanner/model, protocol, series completeness and both software builds.
Source context, not route validation: The FDA packet describes DICOM-compliant CT import and display, cardiac CT post-processing, and reporting; compatibility with a specific PACS, RIS, EHR, interface engine, and local routing configuration requires acceptance testing.
Scope: Exact FDA submission.
Name gateways, destinations, transfer rules and failure visibility; a DICOM statement does not prove a route.
Source context, not route validation: The exact FDA package describes the Coronary Plaque Module running on macOS or Microsoft Windows computer operating systems and able to be integrated into image viewing software such as Circle's cvi42 Software Application. Current hosting, data flow, and commercial configuration require vendor confirmation.
Scope: Exact FDA submission. Packet wording: "Computer operating system macOS, Microsoft Windows" … "The Coronary Plaque Module can be integrated into an image viewing software intended for visualization of cardiac images, such as Circle’s FDA-cleared cvi42 Software Application.". Read from the exact FDA decision document on 2026-11-14; this is the release-level description, not current commercial configuration.
Confirm processing location, queue ownership, exclusions and exact AI build.
Source context, not route validation: Calcified, non-calcified, low-attenuation, and total plaque volumes and burdens; remodeling index; diameter- and area-based stenosis; lesion length; on-screen results and a Coronaries Plaque Module report.
Scope: Exact FDA submission.
Confirm object classes, units, references and whether findings, overlays or measurements reach their intended destination.
Unresolved route: Calcified, non-calcified, low-attenuation, and total plaque volumes and burdens; remodeling index; diameter- and area-based stenosis; lesion length; on-screen results and a Coronaries Plaque Module report.
Scope: Exact FDA submission.
Confirm the named viewer/worklist/report build, display behavior and report transfer. Output support alone does not establish this endpoint. The displayed source describes output, not validated end-to-end delivery.
Unresolved route: Not established for the exact route.
Scope: Scope not established.
Name the local, platform and AI supplier support owners and escalation path.
Planned local route tests
No tests below have been performed or accepted.
Patient/study identity (planned). Use approved non-patient test data to verify identifiers, accession and result-to-study linkage at every hop.
Study completeness (planned). Test missing views/series, partial transfer, late arrivals, priors and unsupported acquisition inputs; confirm explicit refusal or fallback.
Ordering and duplicates (planned). Send out-of-order, repeated and corrected studies; verify worklist order, deduplication and no misleading stale results.
Report transfer (planned). Verify output object types, annotations, units, report content, destination and availability of original images.
Access (planned). Verify authorized roles, audit trail, denied access and support ownership at each destination.
Latency and failures (planned). Agree a workload and turnaround target; test queues, timeouts, missing results and fallback reading.
Updates and rollback (planned). Define version change control, revalidation triggers, stop-use criteria and a tested rollback route.
Local implementation checklist
Agree the evidence and acceptance owner with your team and suppliers. Checkmarks apply to this page only and are not acceptance receipts.
The exact FDA package describes the Coronary Plaque Module running on macOS or Microsoft Windows computer operating systems and able to be integrated into image viewing software such as Circle's cvi42 Software Application. Current hosting, data flow, and commercial configuration require vendor confirmation.
Exact FDA submission
Checked 2026-11-14
Packet wording: "Computer operating system macOS, Microsoft Windows" … "The Coronary Plaque Module can be integrated into an image viewing software intended for visualization of cardiac images, such as Circle’s FDA-cleared cvi42 Software Application.". Read from the exact FDA decision document on 2026-11-14; this is the release-level description, not current commercial configuration.
The FDA packet describes DICOM-compliant CT import and display, cardiac CT post-processing, and reporting; compatibility with a specific PACS, RIS, EHR, interface engine, and local routing configuration requires acceptance testing.
Circle describes the current cvi42 Plaque family as on-premise and says data need not be sent to an outside reading service; the official page is not a scoped security attestation for the K251027 release.
Use is limited to qualified medical professionals experienced in cardiovascular CT; local training and competency for plaque editing, report review, and failure handling remain site responsibilities.
Circle describes current cvi42 Plaque as on-premise, AI-enabled plaque quantification integrated into the CT workflow without sending data to an outside reading service.
product family · checked 2026-09-07
Current family capability; verify whether the installed K251027 release, licensing, and local integration match this description.
Circle's regulatory page lists cvi42 FDA 510(k) K251027; the page does not establish every current family feature for that exact cleared configuration.
Sources & review detailsFDA identity, research record, source ledger, and history
Regulatory identity
FDA record and catalog context
The FDA listing establishes the regulatory identity. It does not by itself establish local workflow fit, pricing, security, or performance in your environment.
This audit distinguishes completed source review from fields that have not yet been researched.
Human reviewedStatus
2026-09-07Last searched
24Fields reviewed
13Source classes checked
0Screened PubMed leads
0Screened trial leads
0Unreviewed FDA recall leads
The stored PubMed and ClinicalTrials.gov candidate arrays were screened and were empty. No paper or trial was promoted; empty stored arrays do not establish that no external literature or trials exist. The current discovery snapshot contains 0 PubMed and 0 ClinicalTrials.gov candidate records; its dated, count-matched human screening remains current. Unlinked candidates remain quarantined. Native FDA recall identifiers produced 0 postmarket candidate records; 0 have been reviewed (0 published, 0 rejected) and 0 remain unreviewed.
Candidate leads were screened against the exact product and tested version. Unlinked records remain quarantined.
Source classes: fda ai list, fda decision summary, acr ai central product, vendor product page, vendor regulatory page, payer policy, fda device recall, literature index, trial registry, stored candidate metadata, pubmed, clinical trials, openfda device recall
Field review details
Recorded state, verification date, notes and sources for fields without a publishable value. Conflicting records stay explicitly unsettled here; no plain settled value is shown for them.
Public pricing: Not publicly available - checked 2026-09-07 - Exact FDA submission
No public list price or contract unit for the exact K251027 configuration was established in the reviewed official sources.
Authorized purpose: Adjunctive opportunistic detection and quantification of aortic valve calcification during routine clinical-care chest CT review; a physician reviews the informational ROI and estimated calcium burden and decides any further action.
Authorized purpose: vascuCAP analyzes contrast multidetector CT of arterial vessels to support atherosclerosis stratification with color maps, three-dimensional views, multiplanar reformats, and measurements for physician review.
Copy this public context and add the field, proposed wording and original source before sending. Nothing here is submitted automatically. Form-specific prefill has not been verified.
Permission to display a submission is not evidence verification. A submission enters editorial review; it does not approve a public change. Form availability, data entry, receipt, review and publication are separate steps. Data entry and receipt remain unverified.
Accepted repository change history
No entry has been added to this scoped change history for this record. This is not proof that the record never changed.